RMTI Rockwell Medical, Inc.
Listings ·
Nasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.
Rockwell Medical's one-for-ten reverse split takes effect at 12:01 a.m. Eastern Time on July 1, 2026. The certificate was filed June 24, and the company says fractional shares will be paid in cash at the June 30 closing price, adjusted by the company.
Holders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.
DEK:Rockwell Medical's proxy asks holders to approve a reverse split at a virtual meeting on June 12, 2026. Approval needs a majority of the votes cast, and the company's 2025 net loss was $5.3 million.
Rockwell Medical may sell up to $25,000,000 of stock through Cantor Fitzgerald, which takes a commission of up to 3.0%. At the assumed $4.43 price, the filing says new buyers would face an immediate dilution of $3.33 a share.
Rockwell Medical, Inc. is a healthcare company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products for dialysis providers worldwide. It is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell manufactures its hemodialysis concentrates under current Good Manufacturing Practices. The text names CitraPure, Dri-Sate, RenalPure and SteriLyte as its registered trademarks. The Business section also states that the company files its annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC, and makes them available free of charge on its website.
| Product or program | What it is | Stage |
|---|---|---|
| Hemodialysis concentrates | Liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States | commercially distributed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $0 | $19,000 |
| Net income (loss) | -$5.3 million | -$480,000 |
| Cash from operations | -$659,000 | $4.2 million |
| Cash and equivalents | $10.7 million | $15.7 million |
| Short-term investments | $14.3 million | $5.9 million |
Our latest story on this, dated Jun 29, 2026: "Rockwell Medical sets 1-for-10 reverse stock split for July 1, 2026". The story links the filing or release it is based on. Read the story.
Rockwell Medical, Inc. trades under the ticker RMTI on NASDAQ.
Rockwell Medical, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Rockwell Medical, Inc. is 1041024. Its filings are on SEC EDGAR.
4,030,465 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Rockwell Medical, Inc. under United States.
Our directory classifies Rockwell Medical, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Rockwell Medical, Inc. is US7743744093.
aibio.space lists Rockwell Medical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Rockwell Medical, Inc. is a healthcare company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products for dialysis providers worldwide. It is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States.
Hemodialysis concentrates: Liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States Stage: commercially distributed.
Rockwell Medical, Inc. reported a net loss of $5.3 million for the fiscal year ended Dec 31, 2025, and used $659,000 of cash in operations, per its annual report to the SEC.
$0 in the fiscal year ended Dec 31, 2025, per its annual report.
$10.5 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio